Kite announces positive clinical results of Anti-CD19 Car T Cells

Kite announces positive clinical results of Anti-CD19 CAR T Cells Kite Pharma announced the publication in The Lancet of clinical results demonstrating the potential to treat relapsed or refractory acute lymphoblastic leukemia, or ALL, with an anti-CD19 chimeric antigen receptor, or CAR, T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.

http://ift.tt/1D7Ctj8